The drugmaker’s revenue hit $5.4 billion in the second quarter, marking a 9 percent increase from last year and exceeding Wall Street’s prediction of $5.15 billion.
Eli Lilly’s earnings growth returned last year after the company struggled through three years of declining sales due to generic drug competition.
While older drugs like Cialis and Forteo recorded strong sales, Eli Lilly’s newer drugs also performed well this quarter.
Trulicity — an injectable diabetes treatment that competes with Denmark-based Novo Nordisk’s popular drug Victoza — hit sales of $201 million. Sales of the two-year-old drug Cyramza, used to treat stomach and lung cancer, jumped 68 percent from the second quarter of 2015 to $147 million.
Eli Lilly’s net income saw a 24.5 percent increase to reach $747.7 million by the end of the second quarter on June 30. The company predicts its large drug portfolio will ensure average annual revenue growth of at least 5 percent through 2020.
More articles on supply chain:
FDA expedites Merck’s experimental Ebola vaccine
FDA rejects drug to treat post-surgical eye pain
Pills laced with fentanyl invade drug market
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.